Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

795
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
795
Physiological Control of Respiration01:23

Physiological Control of Respiration

5.9K
Introduction
Breathing, a seemingly passive process, is regulated by the respiratory center in the brainstem. This center coordinates the involuntary control of respirations, which means it occurs without conscious effort, ensuring a smooth and uninterrupted pattern.
Regulation of Ventilation
The body maintains ventilation by monitoring levels of carbon dioxide (CO2), oxygen (O2), and hydrogen ion concentration (pH) in the arterial blood. Among these factors, the level of CO2 plays a crucial...
5.9K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

466
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
466
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

589
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
589
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

866
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
866
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.0K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell Cycle Checkpoints Cooperate to Suppress DNA- and RNA-Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses.

Cell reports·2020
Same author

Pathogenic characteristics of sputum and bronchoalveolar lavage fluid samples from patients with lower respiratory tract infection in a large teaching hospital in China: a retrospective study.

BMC pulmonary medicine·2020
Same author

Circular RNA circNHSL1 Contributes to Gastric Cancer Progression Through the miR-149-5p/YWHAZ Axis.

Cancer management and research·2020
Same author

Intrinsic Endocardial Defects Contribute to Hypoplastic Left Heart Syndrome.

Cell stem cell·2020
Same author

The development of Coronavirus 3C-Like protease (3CL<sup>pro</sup>) inhibitors from 2010 to 2020.

European journal of medicinal chemistry·2020
Same author

<i>AURKB</i> Promotes the Metastasis of Gastric Cancer, Possibly by Inducing EMT.

Cancer management and research·2020

Related Experiment Video

Updated: Jan 17, 2026

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children
07:27

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children

Published on: August 19, 2020

12.4K

Decoding STAT3: a new frontier in understanding and treating hyperoxic lung injury.

Wulan Li1, Qian Liu1, Wenyan Xiong2

  • 1Department of Anesthesiology, Zigong First People's Hospital, Zigong Academy of Medical Sciences, Zigong, China.

Frontiers in Immunology
|September 19, 2025
PubMed
Summary

High-concentration oxygen therapy can cause lung injury. Targeting the STAT3 pathway shows promise for new treatments to improve safety and reduce hyperoxic lung injury.

Keywords:
STAT3apoptosishyperoxiainflammationlung injuryoxidative stresstherapy

More Related Videos

Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care
14:28

Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care

Published on: May 10, 2024

2.1K
Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
14:48

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Published on: March 21, 2021

5.5K

Related Experiment Videos

Last Updated: Jan 17, 2026

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children
07:27

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children

Published on: August 19, 2020

12.4K
Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care
14:28

Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care

Published on: May 10, 2024

2.1K
Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
14:48

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Published on: March 21, 2021

5.5K

Area of Science:

  • Pulmonary Medicine
  • Molecular Biology
  • Toxicology

Background:

  • High-concentration oxygen (hyperoxia) therapy is essential for hypoxemic emergencies but can cause significant lung injury (HLI).
  • Current treatments like antioxidant or anti-inflammatory agents have limited efficacy against HLI.
  • The molecular mechanisms underlying HLI remain incompletely understood, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To explore the multifaceted role of the Signal Transducer and Activator of Transcription 3 (STAT3) pathway in hyperoxic lung injury (HLI).
  • To review recent advancements in STAT3-targeted therapies for mitigating HLI.
  • To provide a comprehensive understanding of STAT3 signaling in HLI for developing improved treatment strategies.

Main Methods:

  • Literature review focusing on the STAT3 signaling pathway in the context of hyperoxia.
  • Analysis of studies investigating STAT3 activation in lung cells following hyperoxia exposure.
  • Examination of various cell types and disease models relevant to HLI.

Main Results:

  • STAT3 is activated in lung cells during hyperoxia, exhibiting both detrimental and protective functions.
  • Evidence suggests STAT3 plays a complex role in the inflammatory, apoptotic, and antioxidant responses to hyperoxia.
  • The dual role of STAT3 highlights the need for nuanced therapeutic strategies.

Conclusions:

  • STAT3 signaling is a critical mediator in hyperoxic lung injury (HLI).
  • Targeting the STAT3 pathway presents a potential therapeutic avenue for improving hyperoxia therapy safety.
  • Further research into STAT3 mechanisms is crucial for developing effective treatments for HLI.